Join
Live feed
·
PRReleasevia Quantisnow
Corvus Pharmaceuticals Inc. logo

Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA

ByQuantisnow·Wall Street's wire, on your screen.
CRVS· Corvus Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRVS (Corvus Pharmaceuticals Inc.) and more on Quantisnow.

Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA | Quantisnow